Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1948 1
1964 1
1965 26
1966 52
1967 40
1968 63
1969 46
1970 46
1971 62
1972 47
1973 50
1974 52
1975 63
1976 63
1977 66
1978 91
1979 102
1980 93
1981 118
1982 150
1983 162
1984 181
1985 186
1986 231
1987 207
1988 200
1989 210
1990 272
1991 234
1992 280
1993 273
1994 315
1995 349
1996 370
1997 375
1998 361
1999 417
2000 446
2001 515
2002 550
2003 624
2004 763
2005 871
2006 952
2007 899
2008 938
2009 1035
2010 1255
2011 1342
2012 1413
2013 1435
2014 1643
2015 1918
2016 1871
2017 1995
2018 2068
2019 910
2020 27
Text availability
Article attribute
Article type
Publication date

Search Results

26,919 results
Results by year
Filters applied: . Clear all
Page 1
Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study.
Gomez DR, et al. Lancet Oncol 2016 - Clinical Trial. PMID 27789196 Free PMC article.
BACKGROUND: Evidence from retrospective studies suggests that disease progression after first-line chemotherapy for metastatic non-small-cell lung cancer (NSCLC) occurs most often at sites of disease known to exist at baseline. ...FUNDING: MD Anderson Lung Cancer Priority Fund, MD Anderson Cancer Center Moon Shot Initiative, and Cancer Center Support (Core), National Cancer Institute, National Institutes of Health....
BACKGROUND: Evidence from retrospective studies suggests that disease progression after first-line chemotherapy for metastatic non-small-cel …
Role of chemotherapy and targeted therapy in early-stage non-small cell lung cancer.
Nagasaka M and Gadgeel SM. Expert Rev Anticancer Ther 2018 - Review. PMID 29168933 Free PMC article.
Adjuvant platinum based chemotherapy is accepted as standard of care in stage II and III non-small cell lung cancer (NSCLC) patients and is often considered in patients with stage IB disease who have tumors ≥ 4 cm. ...Trials for adjuvant targeted therapy, including adjuvant EGFR-TKI trials and trials of immunotherapy drugs are ongoing and will define the role of these agents as adjuvant therapy....
Adjuvant platinum based chemotherapy is accepted as standard of care in stage II and III non-small cell lung cancer (NSCLC) patients …
Unravelling the biology of SCLC: implications for therapy.
Sabari JK, et al. Nat Rev Clin Oncol 2017 - Review. PMID 28534531 Free PMC article.
Small-cell lung cancer (SCLC) is an aggressive malignancy associated with a poor prognosis. First-line treatment has remained unchanged for decades, and a paucity of effective treatment options exists for recurrent disease. ...High expression of the inhibitory Notch ligand Delta-like protein 3 (DLL3) in most SCLCs has been linked to expression of Achaete-scute homologue 1 (ASCL1; also known as ASH-1), a key transcription factor driving SCLC oncogenesis; encouraging preclinical and clinical activity has been demonstrated for an anti-DLL3-antibody-drug conjugate. ...
Small-cell lung cancer (SCLC) is an aggressive malignancy associated with a poor prognosis. First-line treatment has remained unchang …
New and emerging targeted treatments in advanced non-small-cell lung cancer.
Hirsch FR, et al. Lancet 2016 - Review. PMID 27598681
This area of research progresses day by day, with novel target discoveries, novel drug development, and use of novel combination treatments. ...We review recent progress in the development of targeted treatments for patients with advanced non-small-cell lung cancer, especially focusing on data from published clinical trials....
This area of research progresses day by day, with novel target discoveries, novel drug development, and use of novel combination trea …
Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component.
Yang JC, et al. J Clin Oncol 2017 - Clinical Trial. PMID 28221867 Free article.
Patients and Methods Patients with EGFR-TKI-pretreated EGFRm- and T790M-positive advanced non-small-cell lung cancer (NSCLC) received once-daily osimertinib 80 mg. ...Interstitial lung disease (grouped terms) was reported in eight patients (4%; grade 1, n = 2; grade 3, n = 3; grade 5, n = 3). ...
Patients and Methods Patients with EGFR-TKI-pretreated EGFRm- and T790M-positive advanced non-small-cell lung cancer (NSCLC) received …
Osimertinib: A third-generation tyrosine kinase inhibitor for treatment of epidermal growth factor receptor-mutated non-small cell lung cancer with the acquired Thr790Met mutation.
Bollinger MK, et al. J Oncol Pharm Pract 2018 - Review. PMID 28565936
Osimertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) approved for the treatment of metastatic EGFR T790M mutation-positive non-small cell lung cancer (NSCLC) in patients failing previous TKI therapy. ...Serious, but rare, adverse events include pneumonitis, interstitial lung disease-like events, QT interval prolongation, and reduced ejection fraction. ...
Osimertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) approved for the treatment of meta …
Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint.
Hellmann MD, et al. Lancet Oncol 2014 - Review. PMID 24384493 Free PMC article.
Improvements in outcomes for patients with resectable lung cancers have plateaued. Clinical trials of resectable non-small-cell lung cancers with overall survival as the primary endpoint require a decade or longer to complete, are expensive, and limit innovation. ...We support the incorporation of major pathological response as a surrogate endpoint for survival in future neoadjuvant trials of resectable lung cancers. ...
Improvements in outcomes for patients with resectable lung cancers have plateaued. Clinical trials of resectable non-small-cell lu
First-Line Therapies for Metastatic Lung Adenocarcinoma Without a Driver Mutation.
Bodor JN, et al. J Oncol Pract 2018 - Review. PMID 30205771
Lung cancer is the leading cause of cancer-related death worldwide. The majority of these cancers are non-small-cell lung cancer, of which adenocarcinoma is the most common histologic subtype. ...This review will outline the currently available therapies for the first-line treatment of metastatic adenocarcinoma that do not possess a driver mutation and provide a recommended approach and algorithm by which to select the best first-line therapy....
Lung cancer is the leading cause of cancer-related death worldwide. The majority of these cancers are non-small-cell lung canc
Sequencing Therapy for Genetically Defined Subgroups of Non-Small Cell Lung Cancer.
Yu HA, et al. Am Soc Clin Oncol Educ Book 2018 - Review. PMID 30231382 Free article.
The practice of precision medicine for patients with metastatic non-small cell lung cancer (NSCLC), particularly those patients with adenocarcinoma histology (the predominant subtype of NSCLC), has become the accepted standard of care worldwide. Implementation of prospective tumor molecular profiling and rational therapeutic decision-making based on the presence of recurrently detected oncogenic "driver" alterations in the tumor genome has revolutionized the way that lung cancer is diagnosed and treated in the clinic. ...
The practice of precision medicine for patients with metastatic non-small cell lung cancer (NSCLC), particularly those patients with …
Afatinib: A Review in Advanced Non-Small Cell Lung Cancer.
Keating GM. Target Oncol 2016 - Review. PMID 27873136
In the overall population of patients receiving first-line treatment for advanced lung adenocarcinoma with activating EGFR mutations, afatinib significantly prolonged PFS, but not OS, compared with pemetrexed plus cisplatin (LUX-Lung 3 trial) or gemcitabine plus cisplatin (LUX-Lung 6 trial). However, in both LUX-Lung 3 and LUX-Lung 6, OS was significantly prolonged in the subgroup of patients with deletions in exon 19 receiving afatinib versus chemotherapy. ...
In the overall population of patients receiving first-line treatment for advanced lung adenocarcinoma with activating EGFR mutations, …
26,919 results
Jump to page
Feedback